Patients may require life-long monitoring and a collaborative engagement with subspecialists to keep well in the long -term,” ...

Concomitant radiotherapy plus temozolomide significantly increased progression-free survival versus radiotherapy alone in IDH ...

In resectable, locally advanced esophageal squamous cell carcinoma, neoadjuvant Tyvyt plus chemoradiotherapy led to an ...

T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer.

Several new treatment options for patients with breast cancer have emerged over the last few years, including more oral medications like trastuzumab deruxtecan (Enhertu) and pembrolizumab (Keytruda), ...

In the first randomized trial of its kind, researchers found that adding chemoradiation to adjuvant chemotherapy did not ...

An analysis of ctDNA testing for early detection of recurrence showed that test had high sensitivity across multiple sites of recurrence, including liver (96%), lymph nodes (89%), abdominopelvic (86%) ...

Single-agent adjuvant chemotherapy did not improve overall survival when compared to no adjuvant chemotherapy.

prescription fluoride (for patients with xerostomia); surgical debridement or resection Expected incidence rates are for the setting of curative-intent radiotherapy (definitive or adjuvant), unless ...

The phase III ESCORT-NEO trial evaluated camrelizumab in combination with chemotherapy versus chemotherapy alone in the neoadjuvant setting and found that the former improved the ...

Neoadjuvant CRT plus sintilimab yielded a higher pCR rate than neoadjuvant chemo plus sintilimab in patients with locally ...

Presented in part at the 2023 Annual Meeting of the American Society of Radiation Oncology (ASTRO), San Diego, CA, October 1-4, 2023. Supported by grants U10CA180868 (NRG Oncology Operations), UG1CA ...